Clinical trial
A Phase 3, Multicenter, Open-Label Study to Assess the Long-Term Safety of REL-1017 as a Treatment of Major Depressive Disorder
NCT04855760 is registered in ClinicalTrials.gov with Relmada Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Multicenter, Open-Label Study to Assess the Long-Term Safety of REL-1017 as a Treatment of Major Depressive Disorder
- Lead sponsor
- Relmada Therapeutics, Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- April 1, 2021
- Completion date
- July 27, 2023
- Enrollment
- 627 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.